Compare LBRX & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | ESRT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 836.1M |
| IPO Year | 2025 | 2012 |
| Metric | LBRX | ESRT |
|---|---|---|
| Price | $44.41 | $4.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $46.60 | $6.35 |
| AVG Volume (30 Days) | 388.7K | ★ 1.9M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $768,270,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | N/A | $1.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.05 |
| 52 Week Low | $13.40 | $4.61 |
| 52 Week High | $49.14 | $8.07 |
| Indicator | LBRX | ESRT |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 39.16 |
| Support Level | $20.71 | N/A |
| Resistance Level | N/A | $5.85 |
| Average True Range (ATR) | 3.19 | 0.20 |
| MACD | 0.28 | -0.05 |
| Stochastic Oscillator | 69.16 | 17.74 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.